# TRAVERE THERAPEUTICS, INC. (TVTX) FY2026 Q2 P&L / Income Statement

- Company: TRAVERE THERAPEUTICS, INC. (TVTX)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-04, accession number 0001438533-26-000063
- Page: https://plicit.ai/financials/tvtx/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/tvtx-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service (3 categories)

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (3 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenue**: 169,584,000 US dollars
- **Cost of goods sold**: 2,174,000 US dollars
- **Gross profit (calculated)**: 167,410,000 US dollars
- **Operating expenses (calculated)**: 163,456,000 US dollars
- **Operating income (loss)**: 3,954,000 US dollars
- **Total other (expense) income, net**: negative 38,955,000 US dollars
- **Loss from continuing operations before income tax**: negative 35,001,000 US dollars
- **Income tax benefit (provision) on continuing operations**: negative 204,000 US dollars
- **Net loss**: negative 34,797,000 US dollars
- **FILSPARI**: 141,078,000 US dollars
- **Tiopronin products**: 20,274,000 US dollars
- **License and collaboration revenue**: 8,232,000 US dollars
- **Selling, general and administrative**: 96,112,000 US dollars
- **Research and development**: 60,283,000 US dollars
- **Royalty expense**: 7,061,000 US dollars
- **Loss from discontinued operations, net of tax**: 0 US dollars. Reported below-tax contribution to net income.

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.

## Chart details: Revenue by Product and Service (2 categories)

- Page: https://plicit.ai/financials/tvtx/fy2026-q2-income-statement/revenue-by-product-and-service-2-categories
- Chart image: https://plicit.ai/charts/tvtx-fy2026-q2-revenue-by-product-and-service-2-categories-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (2 categories). Revenue and costs use their disclosed categories.

- **Total revenue**: 169,584,000 US dollars
- **Cost of goods sold**: 2,174,000 US dollars
- **Gross profit (calculated)**: 167,410,000 US dollars
- **Operating expenses (calculated)**: 163,456,000 US dollars
- **Operating income (loss)**: 3,954,000 US dollars
- **Total other (expense) income, net**: negative 38,955,000 US dollars
- **Loss from continuing operations before income tax**: negative 35,001,000 US dollars
- **Income tax benefit (provision) on continuing operations**: negative 204,000 US dollars
- **Net loss**: negative 34,797,000 US dollars
- **Net product sales revenue**: 161,352,000 US dollars
- **License and collaboration revenue revenue**: 8,232,000 US dollars
- **Net product sales cost of revenue**: 2,174,000 US dollars
- **License and collaboration revenue cost of revenue**: 0 US dollars
- **Selling, general and administrative**: 96,112,000 US dollars
- **Research and development**: 60,283,000 US dollars
- **Royalty expense**: 7,061,000 US dollars
- **Loss from discontinued operations, net of tax**: 0 US dollars. Reported below-tax contribution to net income.

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.